Clinical trial
SIPO1-AD: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Siponimod in Patients With Mild Alzheimer's Disease
NCT06639282 is registered in ClinicalTrials.gov with St. Joseph's Hospital and Medical Center, Phoenix as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- SIPO1-AD: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Siponimod in Patients With Mild Alzheimer's Disease
- Lead sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- August 26, 2025
- Completion date
- October 31, 2029
- Enrollment
- 105 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
alzheimer disease, cognitive impairment, mild, mci with increased risk for alzheimer disease, mild alzheimer disease